Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. (NCT05620498) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-08 |
Track Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer automatically
Every clearance here is in the API, with alerts when new ones post.